- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Colorectal cancer
- Meeting Date: May 2021
- Public Summary Document (PSD) May 2021 PBAC Meeting - (PDF 1720KB)
- Public Summary Document (PSD) May 2021 PBAC Meeting - (Word 393KB)
Encorafenib – May 2021
ENCORAFENIB Tablet 50 mg, Tablet 75 mg, Braftovi®
Last updated
27 August 2021